Xcout Intel
SeqOne Genomics
SeqOne Genomics is a certified medical device and technology company providing a smart genomics platform that leverages artificial intelligence to support genomic data analysis.
Subscribe to see SeqOne Genomics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
SeqOne Genomics at a glance
SeqOne Genomics is a biotechnology company headquartered in France. Its most recent funding round, Growth Round, raised $20.8M in May 2025. Xcout tracks 3 named people at SeqOne Genomics, including Martin Dubuc (Chief Executive Officer).
SeqOne Genomics leadership
- Martin DubucChief Executive Officer
- Nicolas PhilippePresident & CPSO
- Dr. Jonathan SheldonBoard of Directors
SeqOne Genomics funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Growth Round | $20.8M | 4 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
SeqOne Genomics competitors
A few of SeqOne Genomics's closest competitors — see the full list of competitors and alternatives →
Biotasmart is a health-tech startup headquartered in Valencia, Spain, founded in 2024 to provide at-home gut microbiota testing using metagenomic sequencing and artificial intelligence.
M42 is a global tech-enabled healthcare company headquartered in Abu Dhabi. It utilizes innovative clinical solutions, genomics, and artificial intelligence to deliver precise, patient-centric medical care.
gMendel is a medical technology company founded in 2020 that develops an AI-powered, cloud-based platform combining genomics with artificial intelligence. The company provides decision support software designed to enable faster, more accurate, and scalable diagnosis of genetic disorders.
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
SwitchPoint Bio Holding, Inc. operates a platform that combines precision epigenomics and artificial intelligence to analyze cellular biology from blood samples. The company provides biomarker discovery, patient stratification, and treatment response mechanism readouts to support drug development and clinical research.
WittGen Inc. provides a virtual cell-to-patient profiling technology powered by single-cell generative AI for clinical leaders and biopharmaceutical researchers. The company's platform transforms archived bulk RNA samples and pathological image data into regulator-ready patient stratification insights and cellular-level biomarkers to de-risk clinical trials and accelerate oncology drug development.
Get SeqOne Genomics's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on SeqOne Genomics in Xcout Intel
- 3 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access